Scientists discover a hidden brain rhythm that could improve Parkinson’s treatment
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Cologne-led researchers identified a specific brain network and its 20-35 Hz beta rhythm that appears to drive the benefits of deep brain stimulation for Parkinson's disease, publishing the work in the journal Brain.
- The study combined implanted DBS electrode recordings and magnetoencephalography (MEG) in 50 patients and 100 brain hemispheres—the first time electrophysiology and brain imaging have been used simultaneously to characterize the DBS response network in both space and time.
- The team mapped functional connections between the subthalamic nucleus and frontal cortex areas, finding that this network communicates primarily at 20-35 Hz and that the strength of this connection correlated with how much individual patients' motor symptoms improved after electrode implantation.
- Professor Dr. Andreas Horn (University of Cologne, computational neurology) led the study, with Dr. Bahne Bahners (Düsseldorf University Hospital) as first author; collaborators came from University Hospitals of Cologne and Düsseldorf, Harvard Medical School, and Charité Berlin.
- Per Bahners, the rhythm acts as a 'communication channel' between the subthalamic nucleus and the cerebral cortex that may mediate DBS's therapeutic effects and could let clinicians adjust stimulation settings more precisely for patients who have not yet benefited optimally.
- Follow-up studies examining the causal effects of deep brain stimulation on brain networks are already underway, with the current work funded primarily by the Professor Klaus Thiemann Foundation.
Why it matters: Deep brain stimulation of the subthalamic nucleus is already an established Parkinson's therapy, but patient responses vary and current settings work suboptimally for some. By tying DBS response to a measurable 20-35 Hz network linking the subthalamic nucleus to frontal cortex, the Cologne team gives clinicians a concrete target for personalizing electrode placement and stimulation parameters—a meaningful step toward individualized treatment for patients who don't respond well to standard DBS.
Ask SkimNews
